A combination of immunoadjuvant nanocomplexes and dendritic cell vaccines in the presence of immune checkpoint blockade for effective cancer immunotherapy  

作　　者：Manh-Cuong Vo Seo-Yeon Ahn Tan-Huy Chu Saji Uthaman Shammer Pillarisetti Tung Nguyen Thanh Uong Thangaraj Jaya Lakshmi Mihee Kim Ga-Young Song Sung-Hoon Jung Deok-Hwan Yang Jae-Sook Ahn Hyeoung-Joon Kim In-Kyu Park Je-Jung Lee 

机构地区：[1]Institute of Research and Development,Duy Tan University,Danang,Vietnam [2]Research Center for Cancer Immunotherapy,Chonnam National University Hwasun Hospital,Hwasun,Jeollanamdo,Republic of Korea [3]Department of Hematology-Oncology,Chonnam National University Hwasun Hospital,Chonnam National University Medical School,Gwangju,Republic of Korea [4]Department of Polymer Science and Engineering,Chungnam National University,Daejeon,Republic of Korea [5]Department of Biomedical Science,Chonnam National University Medical School,Gwangju,Republic of Korea [6]Department of Radiation Oncology,Chonnam National University Hwasun Hospital,Chonnam National University Medical School,Gwangju,South Korea View author publications

出　　处：《Cellular & Molecular Immunology》2021年第6期1599-1601,共3页中国免疫学杂志（英文版）

基　　金：supported by grants from the Basic Science Research Program through the National Research Foundation of Korea(NRF);funded by the Ministry of Education,Science and Technology(2018R1A5A2024181,2020R1A2C2010098).

摘　　要：Nanovaccines are used as delivery platforms for antigens and adjuvants, which activate antigen-presenting cells (APCs) and enhance anticancer immune responses.1,2 Researchers have recently developed a self-assembled nanocomplex using a polysorbitol-co-PEI (PSPEI) polymer complexed with poly(I:C) (PIC). By binding to different surface proteins, this nanocomplex enhances the intracellular delivery of cargos and induces potent anticancer immune responses against melanoma cells.3 We have previously demonstrated that PD-1/PD-L1 blockade enhanced the efficacy of DC-based cancer immunotherapy.4,5 Moreover, the combination of nanomedicines and PD-L1 blockade has been reported to enhance CD8+ T cell activation and inhibit immunosuppressive cells within the tumor microenvironment.6 In the present study, we investigated the therapeutic efficacy of a combinatorial treatment comprising the immunoadjuvant nanocomplex PSPEI-PIC, a DC vaccine, and PD-L1 blockade in a murine colon cancer model.

关 键 词：ADJUVANT vaccines IMMUNOTHERAPY 

分 类 号：R730.51[医药卫生—肿瘤]